Abstract Non-alcoholic fatty liver disease (NAFLD) is increasing worldwide and has become the greatest potential risk for cirrhosis and hepatocellular carcinoma
The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Yulan Egan Aug 21, 2024 6 min read Across the past two years, GLP-1 agonistsa class of drugs that treat type 2 diabetes (T2D) and obesityhave not only become a major source of industry discourse, but a household name
It enhances postprandial insulin secretion in a glucose-dependent manner and binds to the GLP-1 receptor (GLP-1R), a class B1 G-protein-coupled receptor widely expressed across multiple organs, including the endocrine pancreas, gastrointestinal tract, heart, kidneys, lungs, central nervous system, adipose tissue, immune cells, and even chondrocytes, the primary cells of articular cartilage (1)
The remaining 30 eligible patients were randomized equally into two groups: 15 patients received antivenom only (ASV group), and 15 received a combination of antivenom and N-acetylcysteine (ASV + NAC group)
Speak with our Care Coordinator - free 15-minute metabolism & hormone consultation
